Is the Pharmaceutical Innovation Model Broken? And can Open Innovation Mend it?
October 6, 2013 Editor 0
This IM Channel One Ask the Expert Q&A hosted by NineSigma shares hands-on experiences on how open Innovation can be applied to mitigate operator bias in the pharma industry. By formulating business cases that address global healthcare needs, the pharmaceutical industry can open new avenues of innovation that are built on existing solid assets, developing accessory devices and services, creating user communities (medical and/or patient) and strategies to defend against the generic erosion of revenue.
Go to Source
- Leading Innovation in Multinational Subsidiaries – Part 3
- Mind the Gap! 5 Tips on How to Align Your Boss’ Perception of Innovation Maturity with Reality
- Big Companies, Visionary Leaders Set to Unleash Big Company Innovation
- Negawatt in the making: Ghanaians host the first energy efficiency Challenge
- Getting more out of nature: Genetic toolkit finds new maximum for crop yields
- Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: a randomised, double-blind, placebo-controlled, dose-finding, phase 1/2a study.
Subscribe to our stories
- SL Crowd Green Solutions September 21, 2020
- Digital transformation in the banking sector: surveys exploration and analytics August 3, 2020
- Why Let Others Disrupt You? Take the Smart Self-Disruption Journey! August 3, 2020
- 5 Tips for Crowdfunding During the Pandemic August 3, 2020
- innovation + africa; +639 new citations August 3, 2020